My son is the scientist. He has been following Dr. Urano's work more closely than I have. His explanation is that the "small molecule method" Dr. Urano says he favors at the moment, uses small molecules to trigger MANF production within the body to fight wolframs. That is different from our patent. Our patent manufactures "recombinant manf" outside the body and then injects it into the patient to fight wolframs. "At the moment," Dr. Urano seems to prefer the other method over ours.

Postgost over on Yahoo says he thinks Dr. Urano will find his "small molecule" method will introduce toxicity, which our recombinant MANF doesn't. He thinks Urano is using the "small molecules" because it is saving his lab money because it is cheaper than our method of using manufactured recombinant MANF.

Sorry, but that is as deep as I know how to go. Right now, I'm not sure where we are with wolframs. Everyone is excited to read Urano, but I'm not sure they are reading him correctly. There is a bit of a language barrier.

The only thing I'm sure about MANF is that it seems to be a good fit for Retinitis.